Information relating to the compensation elements of Mr. David Meek, Chief Executive Officer until December 31st, 2019 - Global
Information relating to the compensation elements of Mr. David Meek, Chief Executive Officer until December 31st, 2019
Loading...
  • Mediaarrow_down
      < Back
    • Media
    • Press Releases
    • Media Statements
    • Media Library
  • Investors  arrow_down
    < Back
    • Investors
    • Financial Results
    • Corporate News
    • Financial Calendar
    • Investor Events
    • Reports and Accounts
    • Regulated Information

    • Combined Shareholders’ Meeting 2024 (pre announcement page launch)

       Featured Image
  • Partnering
  • Careersarrow_down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
  • Loading...
  • English  EN     Français  FR     EN  arrow_down
    • EnglishEN
    • FrançaisFR
  • Global Global
    < Back
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • Middle East & Africa
    • United States
    • Brazil
    • Canada EN
    • Canada FR
    • Mexico
    • Australia
    • China
    • Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • Greece
    • Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Slovakia
    • Czech Republic
    • Austria
    • Switzerland
    • Middle East
  • Home
  • Companyarrow_down
      < Back
    • Company
    • Company
    • Leadership
    • History
    • Fondation Ipsen
  • Sciencearrow_down
      < Back
    • Science
    • Oncology
    • Rare Disease
    • Neuroscience
    • Products
    • R&D
    • Pipeline
    • Clinical Trials
  • Responsibilityarrow_down
      < Back
    • Responsibility
    • Responsibility
    • Environment
    • Patients
    • People
    • Governance
  • Patientsarrow_down
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Lay Summaries
    • Collaborate with us
  • Stories
Back

Post navigation

Previous
Next

Information relating to the compensation elements of Mr. David Meek, Chief Executive Officer until December 31st, 2019

Information relating to the compensation elements of Mr. David Meek, Chief Executive Officer until December 31st, 2019

- 17 February 2020 - 0 mins read

Post navigation

Previous
Next

Related Documents

  • Information-relating-to-the-compensation-elements-of-Mr.-David-Meek   Download  (123 KB)

Related Reports and Accounts

Global Quality Policy
18 June 2024 0 mins read

Global Quality Policy
EHS Policy
18 June 2024 0 mins read

EHS Policy
ISO 45001-2018
18 June 2024 0 mins read

ISO 45001-2018
ISO 14001-2015
18 June 2024 0 mins read

ISO 14001-2015
Supplier screening
18 June 2024 0 mins read

Supplier screening
Lobbying activities, association management and governance framework for public policy engagement
18 June 2024 0 mins read

Lobbying activities, association management and governance framework for public policy engagement
D E & I achievements for 2023
18 June 2024 0 mins read

D E & I achievements for 2023
Modern Slavery Statement
18 June 2024 0 mins read

Modern Slavery Statement
Human rights position paper
18 June 2024 0 mins read

Human rights position paper
ISO 37001 Certification
18 June 2024 0 mins read

ISO 37001 Certification

IPN price

€113.10

 €1.20 (1.07%)

  • Media
  • Investors
  • Partnering
  • Careers
  • Company
  • Responsibility
  • Patients
  • Stories
  • Annual Report
  • Contact us
Global
LinkedIn Twitter Facebook Instagram Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

Copyright © Ipsen Pharma. All rights reserved - 2023

You are now leaving the Ipsen group website.To continue, please click on Continue?